ESR1 and breast carcinoma: Consistent with the notion that YAP activation inhibits ER+ breast cancer cells, YAP KD increased while overexpression of either wild-type (WT) or a constitutively active form of YAP (YAP-5SA)9 suppressed the growth of both MCF-7 and T47D cells (Fig. 2d, e).